Isis said the unnamed compound takes advantage of its expertise in nucleic acid therapeutics. The company's research is focused exclusively on the therapeutic target, RNA and focuses on disease areas such as ocular, viral and neurodegenerative diseases, and cancer.
“We're pleased to see Merck advancing this molecule in clinical trials. The compound was created out of our productive collaboration,” commented Isis' senior vice president of Research, Frank Bennett.